Crohns Disease Clinical Trials Near You

Crohn's disease trials in 2026 are advancing beyond TNF inhibitors toward more targeted and durable disease control. IL-23 inhibitors (risankizumab, guselkumab, mirikizumab) have demonstrated superior endoscopic remission rates compared to older biologics, with trials now exploring their use as first-line therapy rather than after anti-TNF failure.

JAK inhibitors are expanding into Crohn's: upadacitinib showed significant endoscopic improvement in Phase 3 trials, joining the oral therapy options alongside existing injectable biologics. Selective JAK1 inhibitors aim to provide efficacy while minimizing the safety concerns (cardiovascular events, thrombosis) that prompted boxed warnings on earlier pan-JAK inhibitors.

Anti-trafficking agents (vedolizumab, ontamalimab targeting MAdCAM-1) prevent inflammatory cells from migrating to the gut, and S1P receptor modulators (etrasimod, ozanimod) trap lymphocytes in lymph nodes to reduce intestinal inflammation — all oral options in late-stage testing.

Bowel damage prevention has become a primary trial endpoint. Treat-to-target strategies use regular endoscopy and intestinal ultrasound to verify mucosal healing rather than relying on symptoms alone. Achieving transmural healing (full-thickness intestinal wall healing on cross-sectional imaging) is emerging as the gold standard.

Patient considerations: Crohn's trials typically require active disease confirmed by endoscopy (SES-CD score) and often elevated fecal calprotectin or CRP. Expect colonoscopies at baseline and weeks 12–52. Many trials accept patients who have failed anti-TNF therapy. Stricturing and penetrating disease may exclude you from some trials but qualify you for others specifically targeting complicated Crohn's.